Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07120737

Efficacy and Safety of Spectacle Lenses With H.A.L.T. MAX Technology on High Myopia Control in Children and Adolescents

Children aged 7-14 years with high myopia were randomly assigned to a control group or an intervention group at a 1:1 ratio. The intervention group wore H.A.L.T. MAX lenses for at least 10 hours per day for 2 years, and the control group wore ordinary single-vision (SV) spectacles for at least 10 hours per day. At the 1-year follow-up examination (6-month visit), control subjects whose equivalent spherical diopter change (SER) was ≥0.75 D were switched to H.A.L.T. MAX lenses until the end of year 2. After entering year 2, all remaining control (SV) subjects will be replaced with H.A.L.T. MAX defofocus frames for at least 10 hours per day until the end of year 2. And continue to wear it for at least 10 hours per day. To evaluate the efficacy, safety and compliance of H.A.L.T. MAX lenses in delaying myopia progression in children with high myopia, and to provide a scientific basis for the formulation and practice of public health programs for delaying myopia progression and the risk of blindness and visual impairment caused by high myopia.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

7 year–14 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Shanghai Eye Disease Prevention and Treatment Center (SEDPTC)

Shanghai, Shanghai Municipality, 200336, China

About this study

In a 2-year randomized controlled study, the intervention group wear H.A.L.T. MAX spectacle lenses for more than 10 hours a day for 2 years. During the first year, the control group wore conventional single-vision (SV) spectacles for at least 10 hours per day. At the 6-month follow-up visit, if the spherical equivalent refraction (SER) change in the control group (SV) participants was ≥0.75 D, they were switched to H.A.L.T. MAX spectacle lenses until the end of the second year. In the second year, all remaining control group (SV) participants were transitioned to H.A.L.T. MAX defocus spectacle lenses and continued wearing them until the study concluded. To evaluate the efficacy, safety and compliance of H.A.L.T. MAX lenses for delaying myopia in children with high myopia, and to provide a scientific basis for the development of prevention strategies for children with high myopia.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Voluntary, willing to follow the protocol, able to read and understand the information form and give free and informed consent (for parents/guardian of children subjects) and assent (for subjects aged 7-14 years old);
  • 7-14 years old,regardless of sex;
  • Spherical equivalent refraction (SE) after cyclopegia ≤ -5.00 D and ≥ -9.00D;
  • Anisometropia and Astigmatism ≤2.50D;
  • Best corrected distance visual acuity of at least 0.8 in both eyes;
  • Willing to wear only the spectacles provided by the investigator for all days (>10 hours) during the study without additional interventions;
  • Accept randomization;
  • Able to sign the informed consent form with the accompaniment and understanding of parents or guardians.

Exclusion criteria

  • Allergic or intolerant to cycloplegic drugs;
  • Exclude children on high dose atropine (1%) or red light therapy;
  • Any previous history of myopia control treatment in the previous 30 days, like low dose atropine, defocus spectacles, or thokeratology and acupuncture;
  • History or presence of an ocular disease, strabismus or amblyopia or other binocular vision abnormalities, accommodation dysfunction, and cataract.;
  • History of eye surgery;
  • Ocular or systemic diseases that may be associated with myopia, such as Marfan syndrome, retinopathy of newborns, diabetes, etc;
  • Anatomic or skin factors affecting the wearing of spectacles;
  • Other conditions unsuitable for inclusion (patients with excessive expectations for the effect of the defocus spectacle lenses or desires to try other myopia interventions).

Treatment and study plan

H.A.L.T. MAX spectacles

Device

The Essilor® Stellest® 2.0 lens features a 2 times larger signal area, significantly enhancing the effect of slowing down myopia progression

Primary outcomes

  1. the proportion of change in SER of ≤ -0.75 (D)

    Time frame: at the end of 1-year

    the proportion of change in SER of ≤ -0.75 (D) at the end of 1-year in both groups

Secondary outcomes

  1. The proportion of change in AL of ≥ 0.34 mm

    Time frame: at the end of 1-year

    The proportion of change in AL of ≥ 0.34 mm at the end of 1-year in both groups

Other outcomes

  1. Adaptation outcome

    Time frame: at the end of 1-year

    visual quality, assessed by specify questionnaire.

  2. Adverse events incidence

    Time frame: 1 year

    Number of participants with adverse events (e.g., headache, dizziness) attributed to lens wear.

  3. Exploratory outcomes1

    Time frame: at the end of 2-year

    Changes in SER and AL in the SVL switch over group in the second year.

  4. Exploratory outcomes2

    Time frame: at the end of 2-year

    Changes in choroidal thickness from baseline in the intervention and control group by OCT.

Study contacts

Contact information is provided by the study sponsor or research team.

Xiangui He

CONTACT

[email protected]

021-62675806

Sponsors and collaborators

Lead sponsor

Shanghai Eye Disease Prevention and Treatment Center

Other

Collaborators

  • Essilor International

Registry information

Official study title

Efficacy and Safety of Spectacle Lenses With Maximized Highly Aspherical Lenslets Target Technology (H.A.L.T. MAX) on High Myopia Control in Children and Adolescents: a Randomized Controlled Research

Important dates

Study start
2025
Primary completion
2028
Study completion
2028
First posted
Aug 13, 2025
Registry last updated
Aug 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.